15 September 2022 | Other

Pfizer begins final phase of mRNA-based flu vaccine trials

Pfizer Inc. has begun conducting the final phase of a flu vaccine trial in the United States. The final phase of the trial will involve 25,000 patients. This is one of the first such trials for an mRNA-based flu vaccine.

Pfizer Inc reported that first participants have already received the vaccine shot. Its manufacture is based on the same technology as the common COVID-19 vaccine. The technology was developed jointly with the German organization BioNTech SE.

Between 12,000 and 52,000 people die of influenza in the U.S. each year. But vaccines use strains that require annual replacement before flu season - circulating viruses are constantly evolving.

With the advent of mRNA technology, the ability to change strains in vaccines more quickly has been achieved. Pfizer expects this to provide more accurate strain matching in the future.

Company MarketCheese
Period: 14.11.2026 Expectation: 3500 pips
Sell Bitcoin with $75,000 in view
30 October 2026 117
Period: 14.11.2026 Expectation: 150 pips
Go short on SPX down to $7,500
30 October 2026 135
Brent sell
Period: 29.11.2026 Expectation: 450 pips
Brent crude sell-off targets $105
29 October 2026 109
Period: 12.11.2026 Expectation: 28000 pips
Go long on NVIDIA stock up to $243
29 October 2026 114
Period: 28.11.2026 Expectation: 130 pips
Invest in SPX with 7,850 in view
28 October 2026 147
Period: 28.11.2026 Expectation: 4200 pips
Selling EURUSD down to 1.07000
28 October 2026 162
Go to forecasts